Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment, ...

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...

The U.S. Food and Drug Administration banned Red No. 3 last dye, leading those to think Red Dye No. 40 could be next. How are ...

During his presentation at the J.P. Morgan Healthcare Conference last week, Incyte CEO Hervé Hoppenot took investors on a ...

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the body or cannot be surgically removed.

Discover which popular foods will be affected by the FDA's new ban on Red No. 3, the synthetic dye that adds a vibrant pop of ...

Meanwhile, the HHS website scrubbed search results for the word "abortion," and ReproductiveRights.gov -- a site the Biden ...

A Belgian court dismissed a lawsuit against EU chief Ursula von der Leyen centered on text messages she exchanged with Pfizer ...

The FDA has approved Datroway (datopotamab deruxtecan) to treat adults with unresectable or metastatic, HR+, HER2- breast cancer who have received prior endocrine therapy and chemotherapy.

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...